Risk of thyroid cancer after therapeutic irradiation in adult patients: An Age-Based surveillance, epidemiology, and end results analysis.
Radiation
epidemiology
thyroid cancer
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
24
07
2019
revised:
12
09
2019
accepted:
28
10
2019
pubmed:
21
11
2019
medline:
30
10
2020
entrez:
21
11
2019
Statut:
ppublish
Résumé
One risk of radiation therapy exposure (XRTe) is second primary thyroid cancer (SPTC). Previous reports examined this in children, but no population-based studies have explored XRTe and SPTC across all ages or stratified by histological subtypes. Database study. We report patient characteristics of a Surveillance, Epidemiology, and End Results (SEER) dataset of SPTC (n = 4,669) using χ Extrathyroid extension and node status based on XRTe were similar (P = .684 and P = .776, respectively). XRTe patients were more likely to have smaller tumors (17.6 vs. 19.3 mm, P = .007). XRTe patients were diagnosed with SPTC at younger ages (59.8 vs. 62.7 years, P < .001) without a difference in LS (7.45 vs. 7.50 years, P = .426). Patients aged 1 to 14 years and 15 to 29 years at diagnosis of first cancer are at higher risk of SPTC after XRTe (OR = 1.89, P = .005 and OR = 2.35, P = .001, respectively), unlike patients age 30 to 44 years and 45+ years (OR = 1.03, P = .823 and OR = 0.97, P = .624, respectively). This difference is not present for follicular and medullary SPTC. Patients aged 30+ years receiving radiation therapy (XRT) do not have an increased risk of SPTC. Deliberation is necessary in recommending, planning, and delivering XRT to minimize risk of subsequent malignancy in younger patients. NA Laryngoscope, 130: 2081-2086, 2020.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2081-2086Informations de copyright
© 2019 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398-406.
Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol 2015;114:56-65.
Kumar S, Shah JP, Bryant CS, et al. Second neoplasms in survivors of endometrial cancer: impact of radiation therapy. Gynecol Oncol 2009;113:233-239.
Marti JL, Jain KS, Morris LGT. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid 2015;25:681-687.
Zablotska L, Nadyrov E, Rozhko A, et al. Analysis of thyroid malignant pathological findings identified during three rounds of screening (1997-2008) of a Belarusian cohort of children and adolescents exposed to radioiodines after the Chernobyl accident. Cancer 2015;121:457-466.
Bogdanova TI, Zurnadzhy LY, Nikiforov YE, et al. Histopathological features of papillary thyroid carcinomas detected during four screening examinations of a Ukrainian-American cohort. Br J Cancer 2015;113:1556-1564.
Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus. Cancer 1994;74:748-766.
Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259-277.
Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol 2010;22:395-404.
Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107:2134-2142.
Surveillance, Epidemiology, and End Results (SEER): about SEER. National Cancer Institute. Available at: http://www.seer.cancer/gov/about. Accessed September 23, 2016.
Bhatia S, Yasui Y, Robison LL, et al.; Late Effects Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003;21:4386-4394.
Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330-1336.
Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 1991;325:599-605.
Tucker MA, Jones PH, Boice JD Jr, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. Cancer Res 1991;51:2885-2888.
Roychoudhuri R, Evans H, Robinson D, Møller H. Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 2004;91:868-872.
Michaelson EM, Chen YH, Silver B, et al. Thyroid malignancies in survivors of Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2014;88.3:636-641.
Williams D. Twenty years' experience with post-Chernobyl thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008;22:1061-1073.
Sholl LM, Barletta JA, Hornick JL. Radiation-associated neoplasia: clinical, pathological and genomic correlates. Histopathology 2017;70:70-80.
Ricarte-Filho JC, Li S, Garcia-Rendueles MER, et al. Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. J Clin Invest 2013;123:4935-4944.